EquitySector - HealthcareVery High Risk
Regular
NAV (28-Nov-24)
Returns (Since Inception)
Fund Size
₹232 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+29.38%
— (Cat Avg.)
Equity | ₹197.66 Cr | 85.20% |
Others | ₹34.33 Cr | 14.80% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹22.28 Cr | 9.60% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹22.22 Cr | 9.58% |
Cipla Ltd | Equity | ₹12.83 Cr | 5.53% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹11.85 Cr | 5.11% |
Poly Medicure Ltd | Equity | ₹8.34 Cr | 3.59% |
Aurobindo Pharma Ltd | Equity | ₹8.1 Cr | 3.49% |
Mankind Pharma Ltd | Equity | ₹7.61 Cr | 3.28% |
Lupin Ltd | Equity | ₹7.47 Cr | 3.22% |
Divi's Laboratories Ltd | Equity | ₹6.2 Cr | 2.67% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹6.1 Cr | 2.63% |
Piramal Pharma Ltd | Equity | ₹6.02 Cr | 2.60% |
Ipca Laboratories Ltd | Equity | ₹5.95 Cr | 2.56% |
Glenmark Pharmaceuticals Ltd | Equity | ₹5.91 Cr | 2.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹5.63 Cr | 2.43% |
Strides Pharma Science Ltd | Equity | ₹4.99 Cr | 2.15% |
Ajanta Pharma Ltd | Equity | ₹4.82 Cr | 2.08% |
Apollo Hospitals Enterprise Ltd | Equity | ₹4.8 Cr | 2.07% |
Neuland Laboratories Limited | Equity | ₹4.76 Cr | 2.05% |
Vijaya Diagnostic Centre Ltd | Equity | ₹4.52 Cr | 1.95% |
Fortis Healthcare Ltd | Equity | ₹4.28 Cr | 1.84% |
Net Receivables / (Payables) | Cash | ₹4.01 Cr | 1.73% |
Torrent Pharmaceuticals Ltd | Equity | ₹3.52 Cr | 1.52% |
Ami Organics Ltd | Equity | ₹3.21 Cr | 1.38% |
Global Health Ltd | Equity | ₹3.14 Cr | 1.35% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹3.06 Cr | 1.32% |
Rainbow Childrens Medicare Ltd | Equity | ₹3.06 Cr | 1.32% |
91 DTB 03012025 | Bond - Gov't/Treasury | ₹2.97 Cr | 1.28% |
Jupiter Life Line Hospitals Ltd | Equity | ₹2.93 Cr | 1.27% |
Supriya Lifescience Ltd | Equity | ₹2.89 Cr | 1.25% |
Shaily Engineering Plastics Ltd | Equity | ₹2.45 Cr | 1.06% |
Thyrocare Technologies Ltd | Equity | ₹2.43 Cr | 1.05% |
Gufic Biosciences Ltd | Equity | ₹2.35 Cr | 1.01% |
PB Fintech Ltd | Equity | ₹2.31 Cr | 1.00% |
Alkem Laboratories Ltd | Equity | ₹2.27 Cr | 0.98% |
Shilpa Medicare Ltd | Equity | ₹2.19 Cr | 0.94% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹2.17 Cr | 0.94% |
RPG Life Sciences Ltd | Equity | ₹2.13 Cr | 0.92% |
AstraZeneca Pharma India Ltd | Equity | ₹2.11 Cr | 0.91% |
HealthCare Global Enterprises Ltd | Equity | ₹2.08 Cr | 0.90% |
Kovai Medical Center & Hospital Ltd | Equity | ₹2.04 Cr | 0.88% |
91 DTB 21112024 | Bond - Gov't/Treasury | ₹1.99 Cr | 0.86% |
Blue Jet Healthcare Ltd | Equity | ₹1.85 Cr | 0.80% |
Alembic Pharmaceuticals Ltd | Equity | ₹1.85 Cr | 0.80% |
Laurus Labs Ltd | Equity | ₹1.83 Cr | 0.79% |
182 DTB 12122024 | Bond - Gov't/Treasury | ₹1.69 Cr | 0.73% |
Jubilant Pharmova Ltd | Equity | ₹1.38 Cr | 0.60% |
Suven Pharmaceuticals Ltd | Equity | ₹1.13 Cr | 0.49% |
Gland Pharma Ltd | Equity | ₹0.84 Cr | 0.36% |
191 DTB 12/12/2024 | Bond - Gov't/Treasury | ₹0.6 Cr | 0.26% |
364 DTB 12122024 | Bond - Gov't/Treasury | ₹0.4 Cr | 0.17% |
182 DTB 05122024 | Bond - Gov't/Treasury | ₹0.3 Cr | 0.13% |
364 DTB 09012025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
Large Cap Stocks
27.07%
Mid Cap Stocks
24.55%
Small Cap Stocks
31.53%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹184.92 Cr | 79.71% |
Basic Materials | ₹5.67 Cr | 2.44% |
Financial Services | ₹2.31 Cr | 1.00% |
Standard Deviation
This fund
--
Cat. avg.
15.67%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since February 2024
Since February 2024
Since February 2024
Since April 2024
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹232 Cr | Age 9 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | 44.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | 38.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | 36.2% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | 39.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | 47.8% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | 45.0% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | 40.7% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | 38.6% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | 37.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | 38.2% |
Your principal amount will be at Very High Risk